{"transactions":[{"id":739878,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:34:10.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":15.48,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001245624-26-000002","document":"form4-06122026_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000124562426000002/form4-06122026_080606.xml","form_type":"4"}},{"id":743392,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:26:42.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266095/ownership.xml","form_type":"4"}},{"id":794189,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:14:20.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2526315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI. The Reporting Person disclaims beneficial ownership of the securities directly held by SVP XI. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":804379},"source":{"system":"sec-edgar","filing":"0001193125-26-204494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204494/ownership.xml","form_type":"4"}},{"id":794188,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-05-04T22:14:20.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":6052631,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI. The Reporting Person disclaims beneficial ownership of the securities directly held by SVP XI. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1927159},"source":{"system":"sec-edgar","filing":"0001193125-26-204494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204494/ownership.xml","form_type":"4"}},{"id":794187,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:14:20.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":804379,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI. The Reporting Person disclaims beneficial ownership of the securities directly held by SVP XI. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2731538,"source":{"system":"sec-edgar","filing":"0001193125-26-204494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204494/ownership.xml","form_type":"4"}},{"id":794186,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:14:20.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":1927159,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI. The Reporting Person disclaims beneficial ownership of the securities directly held by SVP XI. This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1927159,"source":{"system":"sec-edgar","filing":"0001193125-26-204494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204494/ownership.xml","form_type":"4"}},{"id":1036213,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33450,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.51,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":33450},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036212,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14545,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.01,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":14545},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036211,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13950,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":13950},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036210,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2032-07-15","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036209,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":37.53,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036208,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.67,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036207,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":21.45,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036206,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14222,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, pursuant to the Merger Agreement, each stock option (\"Option\") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.16,"expiration_date":"2028-04-24","underlying":"Common Stock","underlying_shares":14222},"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036205,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":2194278,"price":8.6,"value":18870790.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the \"Merger Consideration\"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the \"Effective Time\"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is one of the managing members of the general partner of Sofinnova Management X-A, L.L.C., the general partner of Sofinnova Management X, L.P., the general partner of Sofinnova Venture Partners X, L.P., which directly holds the reported securities, and, as such, may be deemed to share voting and investment power over such shares. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners X, L.P."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036204,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25080,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1036203,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-18T20:59:46.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":31603,"price":8.6,"value":271785.8,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the \"Issuer\"), Yosemite Merger Sub, Inc. (\"Purchaser\"), Perseus BidCo US, Inc., a Delaware corporation (\"Parent\"), and Stark International Lux, a Luxembourg private limited liability company (\"Ultimate Parent\"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the \"Merger Consideration\"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the \"Effective Time\"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001245624-25-000004","document":"form4-09192025_120942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000124562425000004/form4-09192025_120942.xml","form_type":"4"}},{"id":1094642,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-07-02T16:20:19.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":33450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer on each vesting date, and are exercisable immediately upon vesting."}],"balance_after":33450,"derivative":{"exercise_price":4.51,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":33450},"source":{"system":"sec-edgar","filing":"0001415889-25-019047","document":"form4-07022025_040713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588925019047/form4-07022025_040713.xml","form_type":"4"}},{"id":1094641,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T16:20:19.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":25080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2026, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":56683,"source":{"system":"sec-edgar","filing":"0001415889-25-019047","document":"form4-07022025_040713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588925019047/form4-07022025_040713.xml","form_type":"4"}},{"id":1106593,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:15:18.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":21850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":21850,"derivative":{"exercise_price":10.95,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":21850},"source":{"system":"sec-edgar","filing":"0000950170-25-087901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025087901/ownership.xml","form_type":"4"}},{"id":1117966,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:46:16.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":4.44,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-016293","document":"form4-06092025_080608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588925016293/form4-06092025_080608.xml","form_type":"4"}},{"id":1163832,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T20:35:09.000Z","date":"2025-04-25","kind":"grant","planned":false,"acquired":true,"shares":142,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $20,625 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":46260,"source":{"system":"sec-edgar","filing":"0001415889-25-011552","document":"form4-04292025_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588925011552/form4-04292025_080405.xml","form_type":"4"}},{"id":1284298,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:15:11.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":114,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $19,375 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":46118,"source":{"system":"sec-edgar","filing":"0001415889-25-003070","document":"form4-02042025_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588925003070/form4-02042025_090207.xml","form_type":"4"}},{"id":1379953,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-29T21:05:09.000Z","date":"2024-10-25","kind":"grant","planned":false,"acquired":true,"shares":153,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $19,375 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":46004,"source":{"system":"sec-edgar","filing":"0001415889-24-025715","document":"form4-10292024_091005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588924025715/form4-10292024_091005.xml","form_type":"4"}},{"id":1398478,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":7310796,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP.  The reporting person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1638236},"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398477,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The entire option award shall vest on the earlier of:  (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":18,"expiration_date":"2034-09-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398476,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":26497,"price":18,"value":476946.0,"ownership":{"direct":false,"nature":"CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\").  Synergy Fund GP is the general partner of Pinnacle LP.  The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Pinnacle LP."}],"balance_after":26497,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398475,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":21814,"price":18,"value":392652.0,"ownership":{"direct":false,"nature":"Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\").  Synergy Fund GP is the general partner of PEAK SP.  The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by PEAK SP."}],"balance_after":21814,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398474,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":18353,"price":18,"value":330354.0,"ownership":{"direct":false,"nature":"CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\").  Synergy Fund GP is the general partner of APEX SP.  The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by APEX SP."}],"balance_after":18353,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398473,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":11113,"price":18,"value":200034.0,"ownership":{"direct":false,"nature":"Sofinnova Synergy Master Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are directly held by Sofinnova Synergy Master Fund LP (\"Synergy Fund\").  Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Synergy Fund.  The reporting person is a managing member of Synergy Fund GP and may be deemed to share voting and investment discretion with respect to securities directly held by Synergy Fund."}],"balance_after":11113,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398472,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":588888,"price":18,"value":10599984.0,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents shares purchased from the Issuer in a private placement transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP.  The reporting person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2227124,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1398471,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:22:43.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":1638236,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614.  The securities have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\").  Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP.  The reporting person is a managing member of SM XI and may be deemed to share voting and investment discretion with respect to securities directly held by SVP XI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the securities directly held by each of:  (i) SVP XI; (ii) Synergy Fund; (iii) APEX SP; (iv) PEAK SP; and (v) Pinnacle LP.  This report shall not be construed as an admission that he is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1638236,"source":{"system":"sec-edgar","filing":"0001415889-24-024044","document":"form4-09272024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000141588924024044/form4-09272024_080939.xml","form_type":"4"}},{"id":1446161,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T21:05:12.000Z","date":"2024-07-26","kind":"grant","planned":false,"acquired":true,"shares":177,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $19,375 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":45851,"source":{"system":"sec-edgar","filing":"0001415889-24-020384","document":"form4-07302024_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588924020384/form4-07302024_090708.xml","form_type":"4"}},{"id":1460543,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":2625,"price":26.0551,"value":68394.6375,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":40851,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460542,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":4661,"price":25.0156,"value":116597.7116,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":38226,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460541,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3657,"price":24.212,"value":88543.284,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.59 to $24.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":33565,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460540,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3630,"price":23.0755,"value":83764.065,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.55 to $23.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":29908,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460539,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":2748,"price":26.0551,"value":71599.4148,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":33114,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460538,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":4878,"price":25.0156,"value":122026.0968,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":30366,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460537,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3828,"price":24.212,"value":92683.536,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.59 to $24.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25488,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460536,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3799,"price":23.0755,"value":87663.8245,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.55 to $23.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":21660,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460535,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":2559,"price":26.0551,"value":66675.0009,"ownership":{"direct":false,"nature":"By CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\"). Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":39661,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460534,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":4544,"price":25.0156,"value":113670.8864,"ownership":{"direct":false,"nature":"By CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\"). Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":37102,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460533,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3565,"price":24.212,"value":86315.78,"ownership":{"direct":false,"nature":"By CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.59 to $24.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\"). Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":32558,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1460532,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T00:04:04.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3538,"price":23.0755,"value":81641.119,"ownership":{"direct":false,"nature":"By CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.55 to $23.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\"). Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":28993,"source":{"system":"sec-edgar","filing":"0001104659-24-077868","document":"tm2418922-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000110465924077868/tm2418922-1_4seq1.xml","form_type":"4"}},{"id":1462431,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-02T21:05:10.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":2964,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2025. The RSUs will become fully vested in the event that the Issuer is subject to a change in control."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":45674,"source":{"system":"sec-edgar","filing":"0001415889-24-019066","document":"form4-07022024_090707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588924019066/form4-07022024_090707.xml","form_type":"4"}},{"id":1478936,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:50:09.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":22000,"derivative":{"exercise_price":0.7682,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-073882","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024073882/ownership.xml","form_type":"4"}},{"id":1480391,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-13T21:01:12.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":14545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer on each vesting date, and are exercisable immediately upon vesting."}],"balance_after":14545,"derivative":{"exercise_price":12.01,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":14545},"source":{"system":"sec-edgar","filing":"0001104659-24-071400","document":"tm2417212-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465924071400/tm2417212-3_4seq1.xml","form_type":"4"}},{"id":1480390,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-13T21:01:12.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":3495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2025, subject to the Reporting Person's continued service to the Issuer on the vesting date."}],"balance_after":31603,"source":{"system":"sec-edgar","filing":"0001104659-24-071400","document":"tm2417212-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465924071400/tm2417212-3_4seq1.xml","form_type":"4"}},{"id":1485273,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":11924138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392738},"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485272,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":25455,"price":17,"value":432735.0,"ownership":{"direct":false,"nature":"By CRESTLINE SUMMIT PINNACLE MASTER, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. (\"Pinnacle LP\"). Synergy Fund GP is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25455,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485271,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":26278,"price":17,"value":446726.0,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - PEAK SP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are directly held by Crestline Summit Master, SPC - PEAK SP (\"PEAK SP\"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":26278,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485270,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":17861,"price":17,"value":303637.0,"ownership":{"direct":false,"nature":"By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP (\"APEX SP\"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":17861,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485269,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":18641,"price":17,"value":316897.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by Sofinnova Synergy Master Fund LP (\"Synergy Fund\"). Sofinnova Synergy GP, LLC (\"Synergy Fund GP\") is the general partner of Synergy Fund. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Synergy Fund. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":18641,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485268,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":470589,"price":17,"value":8000013.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1863327,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1485267,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:38:44.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":1392738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1392738,"source":{"system":"sec-edgar","filing":"0000950170-24-071532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071532/ownership.xml","form_type":"4"}},{"id":1532782,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-30T20:35:30.000Z","date":"2024-04-26","kind":"grant","planned":false,"acquired":true,"shares":210,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $19,375 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":42710,"source":{"system":"sec-edgar","filing":"0001415889-24-011830","document":"form4-04302024_080415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588924011830/form4-04302024_080415.xml","form_type":"4"}},{"id":1572173,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1904,"price":92.3,"value":175739.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date."}],"balance_after":0,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572172,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"price":227.04,"value":1135200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572171,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":201.99,"value":1716915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572170,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":232.41,"value":2905125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":97.59,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572169,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8025,"price":330,"value":2648250.0,"ownership":{"direct":false,"nature":"By Sofinnova Management X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"All shares held by SM X LP. SM X LLC, the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572168,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1372441,"price":330,"value":452905530.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"All shares held by Sofinnova Venture Partners X, LP (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572167,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":330,"value":225390.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"All shares held by Sofinnova Synergy Master Fund, LP (the \"Fund\"). Sofinnova Synergy Fund GP, LLC (the \"GP\"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572166,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990,"price":330,"value":326700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1572165,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T16:30:54.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"price":330,"value":10725000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0001140361-24-013925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000114036124013925/form4.xml","form_type":"4"}},{"id":1665003,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-01-31T16:10:47.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":1252308,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1252308},"source":{"system":"sec-edgar","filing":"0001104659-24-008796","document":"tm244611-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465924008796/tm244611-2_4seq1.xml","form_type":"4"}},{"id":1665002,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:10:47.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":444444,"price":18,"value":7999992.0,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein."}],"balance_after":1696752,"source":{"system":"sec-edgar","filing":"0001104659-24-008796","document":"tm244611-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465924008796/tm244611-2_4seq1.xml","form_type":"4"}},{"id":1665001,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:10:47.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":1252308,"ownership":{"direct":false,"nature":"Sofinnova Venture Partners XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners XI, L.P. (\"SVP XI\"). Sofinnova Management XI, L.P. (\"SM XI LP\") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. (\"SM XI\") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein."}],"balance_after":1252308,"source":{"system":"sec-edgar","filing":"0001104659-24-008796","document":"tm244611-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465924008796/tm244611-2_4seq1.xml","form_type":"4"}},{"id":1666397,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-30T20:05:19.000Z","date":"2024-01-26","kind":"grant","planned":false,"acquired":true,"shares":264,"price":63.79,"value":16840.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":42500,"source":{"system":"sec-edgar","filing":"0001415889-24-002000","document":"form4-01302024_080104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588924002000/form4-01302024_080104.xml","form_type":"4"}},{"id":1700714,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-22T14:21:19.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":644000,"price":58.75,"value":37835000.0,"ownership":{"direct":false,"nature":"by Sofinnova Management VIII, L.L.C."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 644,000 shares of Common Stock of the Issuer received by Sofinnova Management VIII, L.L.C. (\"SM VIII\") from a pro-rata in-kind distribution of Common Stock of the Issuer by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\") without consideration to the partners of SVP VIII in accordance with the limited partnership agreement of SVP VIII. In prior reports, the Reporting Person reported beneficial ownership of 1,550,280 shares of Common Stock of the Issuer held by SVP VIII."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.75 to $59.695, inclusive.The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission,upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"All shares held by SM VIII. Mr. Healy is the managing member of SM VIII. SM VIII is the general partner of SVP VIII. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-128727","document":"tm2333601-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923128727/tm2333601-1_4seq1.xml","form_type":"4"}},{"id":1753090,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-31T21:05:13.000Z","date":"2023-10-27","kind":"grant","planned":false,"acquired":true,"shares":396,"price":42.6,"value":16869.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":42236,"source":{"system":"sec-edgar","filing":"0001415889-23-014636","document":"form4-10312023_091004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923014636/form4-10312023_091004.xml","form_type":"4"}},{"id":1819046,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-01T21:05:14.000Z","date":"2023-07-28","kind":"grant","planned":false,"acquired":true,"shares":328,"price":48.48,"value":15901.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $15,927.20 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":41840,"source":{"system":"sec-edgar","filing":"0001415889-23-011687","document":"form4-08012023_090805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923011687/form4-08012023_090805.xml","form_type":"4"}},{"id":1835584,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-05T21:05:37.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":4255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shares shall vest and become exercisable in full on June 9, 2024. The option shares will become fully vested and exercisable in the event that the Issuer is subject to a change in control."}],"balance_after":4255,"derivative":{"exercise_price":48.66,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":4255},"source":{"system":"sec-edgar","filing":"0001415889-23-010851","document":"form4-07052023_090718.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923010851/form4-07052023_090718.xml","form_type":"4"}},{"id":1835583,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T21:05:37.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 9, 2024. The RSUs will become fully vested in the event that the Issuer is subject to a change in control."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":41512,"source":{"system":"sec-edgar","filing":"0001415889-23-010851","document":"form4-07052023_090718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923010851/form4-07052023_090718.xml","form_type":"4"}},{"id":1846333,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-22T16:16:24.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":1904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":1904,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0000950170-23-029414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000095017023029414/ownership.xml","form_type":"4"}},{"id":1846332,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T16:16:24.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":33490,"source":{"system":"sec-edgar","filing":"0000950170-23-029414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000095017023029414/ownership.xml","form_type":"4"}},{"id":1849201,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T20:56:34.000Z","date":"2023-06-14","kind":"other","planned":false,"acquired":true,"shares":8025,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Management X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares acquired by SM X LP in connection with the SVP X Distribution reported above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"All shares held by SM X LP.  SM X LLC, the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares.  Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":8025,"source":{"system":"sec-edgar","filing":"0001104659-23-073047","document":"tm2319284-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923073047/tm2319284-1_4seq1.xml","form_type":"4"}},{"id":1849200,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T20:56:34.000Z","date":"2023-06-14","kind":"other","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Sofinnova Venture Partners X, LP (\"SVP X\") without consideration to its partners in accordance with the limited partnership agreement of SVP X (the \"SVP X Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"All shares held by SVP X. Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares.  Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":1372441,"source":{"system":"sec-edgar","filing":"0001104659-23-073047","document":"tm2319284-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923073047/tm2319284-1_4seq1.xml","form_type":"4"}},{"id":1855887,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T21:14:02.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":1.63,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-037104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919123037104/doc4.xml","form_type":"4"}},{"id":1860321,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-09T18:00:54.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":13950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date, and are exercisable immediately upon vesting."}],"balance_after":13950,"derivative":{"exercise_price":8.13,"expiration_date":"2033-06-08","underlying":"Common stock","underlying_shares":13950},"source":{"system":"sec-edgar","filing":"0001104659-23-070042","document":"tm2318348-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923070042/tm2318348-2_4.xml","form_type":"4"}},{"id":1860320,"issuer":{"id":75095,"kind":"organization","name":"Y-mAbs Therapeutics, Inc.","symbol":"YMAB"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T18:00:54.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":2330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date."}],"balance_after":28108,"source":{"system":"sec-edgar","filing":"0001104659-23-070042","document":"tm2318348-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923070042/tm2318348-2_4.xml","form_type":"4"}},{"id":1874522,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-30T17:05:29.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":false,"shares":3534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU vested in full on May 25, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU vested in full on May 25, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3534},"source":{"system":"sec-edgar","filing":"0001415889-23-008925","document":"form4-05302023_050502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923008925/form4-05302023_050502.xml","form_type":"4"}},{"id":1874521,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T17:05:29.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":true,"shares":3534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":38762,"source":{"system":"sec-edgar","filing":"0001415889-23-008925","document":"form4-05302023_050502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923008925/form4-05302023_050502.xml","form_type":"4"}},{"id":1917965,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-18T20:10:17.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":285,"price":54.73,"value":15598.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors.  The RSUs were fully vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":35228,"source":{"system":"sec-edgar","filing":"0001415889-23-006658","document":"form4-04182023_080406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923006658/form4-04182023_080406.xml","form_type":"4"}},{"id":1989977,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":6073949,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Dr. Healy and Dr. Katabi are the managing member of SM X LLC and may be deemed to have shared voting and dispositive power over the shares held by SVP X. Each of Dr. Healy and Dr. Katabi disclaims beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989976,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"disposition_to_issuer","acquired":false,"shares":19608,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989975,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":9803,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."}],"balance_after":19608,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989974,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":6000,"price":14.32,"value":85920.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.30 to $14.35 inclusive. Dr. Healy undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Synergy Master Fund, LP (the \"Synergy Fund\"). Sofinnova Synergy Fund GP, LLC (the \"Synergy Fund GP\"), the general partner of the Syngery Fund, may be deemed to have sole voting and dispositive power over such shares. Dr. Healy is a managing member of the Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by the Synergy Fund. Dr. Healy disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":2026334,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":5,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-08T18:29:55.000Z","date":"2023-02-06","kind":"purchase","acquired":true,"shares":285714,"price":7,"value":1999998.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3467156,"source":{"system":"sec-edgar","filing":"0001104659-23-014661","document":"tm235954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923014661/tm235954-1_4seq1.xml","form_type":"4"}},{"id":2052220,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-18T21:35:20.000Z","date":"2023-01-13","kind":"grant","acquired":true,"shares":390,"price":40.01,"value":15603.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully-vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":34943,"source":{"system":"sec-edgar","filing":"0001415889-23-001145","document":"form4-01182023_090112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588923001145/form4-01182023_090112.xml","form_type":"4"}},{"id":2052219,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-18T11:12:34.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":2400,"price":37.7075,"value":90498.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Mr. Healy is a managing member of each of Sofinnova Management VIII, L.L.C. (\"Sofinnova Management VIII\"), Sofinnova Management IX, L.L.C. (\"Sofinnova Management IX\") and Sofinnova Synergy Fund GP, LLC (\"Sofinnova Synergy\"). Sofinnova Management VIII is the general partner of Sofinnova Venture Partners VIII, L.P., Sofinnova Management IX is the general partner of Sofinnova Venture Partners IX, L.P. and Sofinnova Synergy is the general Partner of Sofinnova Synergy Master Fund, LP.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-004509","document":"tm233754-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923004509/tm233754-1_4seq1.xml","form_type":"4"}},{"id":2053627,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T20:43:36.000Z","date":"2023-01-13","kind":"sale","acquired":false,"shares":6027,"price":199.8956,"value":1204770.7812,"ownership":{"direct":false,"nature":"By Sofinnova Management X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"All shares held by SM X LP.  SM X LLC, the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares.  Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-004364","document":"tm233746-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923004364/tm233746-1_4seq1.xml","form_type":"4"}},{"id":2053626,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T20:43:36.000Z","date":"2023-01-12","kind":"other","acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Management X, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares acquired by SM X LP in connection with the SVP X Distribution reported above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"All shares held by SM X LP.  SM X LLC, the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares.  Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":6027,"source":{"system":"sec-edgar","filing":"0001104659-23-004364","document":"tm233746-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923004364/tm233746-1_4seq1.xml","form_type":"4"}},{"id":2053625,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T20:43:36.000Z","date":"2023-01-12","kind":"other","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Sofinnova Venture Partners X, LP (\"SVP X\") without consideration to its partners in accordance with the limited partnership agreement of SVP X (the \"SVP X Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"All shares held by SVP X. Sofinnova Management X, L.P. (\"SM X LP\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. (\"SM X LLC\"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares.  Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein."}],"balance_after":1772441,"source":{"system":"sec-edgar","filing":"0001104659-23-004364","document":"tm233746-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923004364/tm233746-1_4seq1.xml","form_type":"4"}},{"id":2135394,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-18T21:07:08.000Z","date":"2022-10-14","kind":"grant","acquired":true,"shares":344,"price":45.42,"value":15624.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors. The RSUs were fully-vested at the time of issuance. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":34553,"source":{"system":"sec-edgar","filing":"0001415889-22-010699","document":"form4-10182022_091019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588922010699/form4-10182022_091019.xml","form_type":"4"}},{"id":2167262,"issuer":{"id":2635,"kind":"organization","name":"Natera, Inc.","symbol":"NTRA"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-02T20:05:19.000Z","date":"2022-07-08","kind":"grant","acquired":true,"shares":430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the issuance of Restricted Stock Units (\"RSUs\") to the Reporting Person in lieu of quarterly retainer fees of $15,625 for service on the Issuer's Board of Directors.  The previously filed Form 4 inadvertently reported the transaction on Table II.  The RSUs were fully-vested at the time of issuance and should have been reported on Table I as reflected in this amendment.  Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":34209,"source":{"system":"sec-edgar","filing":"0001415889-22-009319","document":"form4a-09022022_080911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000141588922009319/form4a-09022022_080911.xml","form_type":"4/A","original_submission_date":"2022-07-12"}},{"id":2185454,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T15:45:56.000Z","date":"2022-08-11","kind":"purchase","acquired":true,"shares":6000,"price":30,"value":180000.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Synergy Master Fund, LP (the \"Synergy Fund\"). Sofinnova Synergy Fund GP, LLC (the \"Synergy Fund GP\"), the general partner of the Syngery Fund, may be deemed to have sole voting and dispositive power over such shares.  The Reporting Person is a managing member of the Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by the Synergy Fund. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001104659-22-091183","document":"tm2223413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465922091183/tm2223413-1_4seq1.xml","form_type":"4"}},{"id":2185453,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T15:45:56.000Z","date":"2022-08-11","kind":"purchase","acquired":true,"shares":500000,"price":30,"value":15000000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over such shares. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6073949,"source":{"system":"sec-edgar","filing":"0001104659-22-091183","document":"tm2223413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465922091183/tm2223413-1_4seq1.xml","form_type":"4"}},{"id":2191802,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-08-08T17:43:22.000Z","date":"2022-08-05","kind":"exercise","acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":16,"exercise_date":"2020-06-15","expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001593968-22-001315","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000159396822001315/primary_01.xml","form_type":"4"}}],"next_cursor":"2022-08-08T17:43:22.000000Z,2191802"}